Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

71

Enrollment

INDUSTRY

Sponsor class

Stopped program has been put on hold by the sponsor

Conditions

Locally Advanced or Metastatic Urothelial Cell Carcinoma
Urinary Bladder Disease
Urological Diseases

Interventions

DRUG: Vofatamab
DRUG: Docetaxel
DRUG: Placebo

Sponsor

Rainier Therapeutics